ArticleFrontiers in immunology2023

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.

Jamie Frankish et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.